

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-67. (Canceled)

68. (Currently Amended) A ~~cell line derived from a B-cell line which is adapted for serum-free culture and in which the EBNA-1 gene of Epstein-Barr virus is expressed, where a DNA construct comprising a DNA encoding G_α protein or a chimeric G_α protein at least one of the following (1) to (3) is integrated into a chromosomal DNA, where at least one of the following (1) and (2) is optionally integrated into the chromosomal DNA:~~

(1) DNA construct ~~comprising a DNA encoding for expression of~~ a transcription factor necessary for construction of an inducible expression system; and

(2) DNA construct where a reporter gene is ligated at the downstream area of a promoter having a responsive element of a transcription factor; and

~~(3) DNA construct for expression of G_α protein or a chimeric G_α protein.~~

69. (Original) The cell line according to claim 68, wherein the cell line is a Namalwa cell adapted for serum-free culture.

70. (Original) The cell line according to claim 69, wherein the Namalwa cell adapted for serum-free culture is Namalwa KJM-1 cell.

71. (Original) The cell line according to claim 68, wherein the transcription factor necessary for construction of the inducible expression system is a chimeric protein of a ligand binding domain of estrogen receptor and yeast Gal4p.

72. (Original) The cell line according to claim 68, wherein the responsive element of the transcription factor is cAMP responsive element (CRE), TPA responsive element (TRE), NFAT (nuclear factor of activated T cells) responsive element or serum responsive element (SRE).

73. (Original) The cell line according to claim 68, wherein the reporter gene is firefly luciferase gene, *Renilla reniformis* luciferase gene, chloramphenicol acetyltransferase gene, β -galactosidase gene, β -lactamase gene or green fluorescent protein gene.

74. (Original) The cell line according to claim 68, wherein the G α protein is at least one G α protein selected from the group consisting of G α_{16} , G α_{15} , G α_q , G α_{11} , G α_s , G α_i , G α_o , G α_z , G α_{12} , G α_{13} , G α_{gust} , G α_t and G α_{14} .

75. (Original) The cell line according to claim 68, wherein the chimeric G α protein is at least one chimeric G α protein selected from the group consisting of the following (1) to (20):

(1) chimeric G α protein where C-terminal 5 amino acids of G α_s are substituted with C-terminal 5 amino acids of G α_q ;

(2) chimeric G α protein where C-terminal 5 amino acids of G α_s are substituted with C-terminal 5 amino acids of G α_i ;

(3) chimeric G α protein where C-terminal 5 amino acids of G α_s are substituted with C-terminal 5 amino acids of G α_o ;

(4) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α _z;

(5) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α ₁₂;

(6) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α ₁₃;

(7) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α _{gust};

(8) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α _i;

(9) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α ₁₄;

(10) chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α ₁₆;

(11) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α _s;

(12) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α _i;

(13) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α _s;

(14) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α _z;

(15) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α ₁₂;

(16) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α ₁₃;

(17) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α _{gust};

(18) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α ₅;

(19) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α ₁₄; and

(20) chimeric G α protein where C-terminal 5 amino acids of G α _q are substituted with C-terminal 5 amino acids of G α ₁₆.

76. (Original) The cell line according to claim 68, wherein the transcription factor necessary for construction of the inducible expression system is a chimeric protein of a ligand binding domain of estrogen receptor and yeast Gal4p, the promoter having a responsive element of the transcription factor is a promoter having a cAMP responsive element (CRE) and the reporter gene is firefly luciferase gene or *Renilla reniformis* luciferase gene.

77. (Original) The cell line according to claim 68, wherein the transcription factor necessary for construction of the inducible expression system is a chimeric protein of a ligand binding domain of estrogen receptor and yeast Gal4p, the promoter having a responsive element of the transcription factor is a promoter having a cAMP responsive element (CRE), the reporter gene is firefly luciferase gene or *Renilla reniformis* luciferase gene and the chimeric G α protein is a chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α _q or a chimeric G α protein where C-terminal 5 amino acids of G α _s are substituted with C-terminal 5 amino acids of G α _i.

Claims 78-108. (Canceled)